Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher, +13

The Lancet

RheumatologyAutoimmune DiseaseLupusSystemic TreatmentLupus Nephritis +4

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

Paul Emery, Ferdinand C. Breedveld, Stephen Hall, +7

The Lancet

Rheumatoid DisorderRheumatologyMedicineRheumatic DiseasesParallel Treatment Trial +6

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Eun Bong Lee, Roy Fleischmann, Stephen Hall, +9

New England Journal of Medicine

Takayasu arteritis. A study of 32 North American patients.

Stephen Hall, Walter G. Barr, J. T. Lie, +3

PubMed

Vascular DiseaseMayo ClinicVasculitisRenal PathologyThrombosis +19

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

Philip J. Mease, Stephen Hall, Oliver FitzGerald, +9

New England Journal of Medicine

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Edward Keystone, Mark C. Genovese, Lars Klareskog, +11

Annals of the Rheumatic Diseases

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall, +205

The Lancet

Rheumatoid DisorderRheumatologyTofacitinib MonotherapyMedicineRheumatic Diseases +6

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

Joel M. Kremer, Zhanguo Li, Stephen Hall, +11

Annals of Internal Medicine

ImmunologyPharmacotherapyInflammatory ArthritisInflammationRheumatoid Disorder +16

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, +10

Annals of the Rheumatic Diseases

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Mark C. Genovese, Roy Fleischmann, Bernard Combe, +7

The Lancet

Rheumatoid DisorderRheumatologyAnti-inflammatoryRheumatic DiseasesDisease-modifying Anti-rheumatic Drugs +7